Alzamend Neuro FY2025 cash $3.9M, equity $3.9M; $5M financing completed ahead of schedule

Alzamend Neuro, Inc.

Cash of $3.9M at April 30, 2025 vs $0.4M prior year; stockholder equity of $3.9M vs deficit $2.6M.
Net cash from financing activities was $10.4M for FY2025.
Completed $5M private placement in June 2025, months early; investor accelerated purchase of additional $4M preferred stock.
Dosed first patient in May 2025 for AL001 'Lithium in Brain' Phase II studies at Mass General; topline results expected year-end 2025.
ALZN002 immunotherapy trial delayed; actively seeking new CRO after prior CRO terminated in Feb 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.